Project title: THERAPEUTIC TREATMENT METHODS FOR CANCER BASED ON THE PRO-APOPTOTIC PROTEIN ARTS

Company name : SIMETRA PHARM LTD.

TECHNOLOGICAL FIELD
Biotechnology, Health Care,
Pharmaceutical

KEY WORDS
Apoptosis, Cancer, IAP,
Small Molecule Drug

PROJECT SUMMARY
SimeTRA Pharm operates in the rapidly growing pharmaceutical
market section, which is searching for drugs that specifically
trigger the apoptotic process in cancer cells. SimeTRA's
therapies are based on smart proteins that restore the ability of
cancer cells to commit suicide (apoptosis). Particularly, SimeTRA
is using drugs based on ARTS, a proprietary powerful
pro-apoptotic protein. Its first products will be focused on
treating Hematopoietic cancers (Leukemia, Lymphoma and Myeloma).

ART's Advantages:
* In contrast to traditional anti-cancer treatments,
over-expression of ARTS specifically kills cancer cells and not
healthy cells. In fact, experiments conducted by SimeTRA have
shown that normal lymphocytes from healthy donors were not
affected by doses of ARTS five times higher than those needed to
effectively kill cancer cells.
* While ARTS may ultimately replace current cancer treatments, it
may also be used to enhance their efficacy. Cells, which exhibit
loss of ARTS protein, or even reduced levels of ARTS, show
increased resistance to chemotherapy-induced apoptosis. Treatment
of these non responsive cells with ARTS can cause them to regain
their responsiveness to chemotherapy.
* ARTS' mode of action as an IAP antagonist is unique, and so far
it is the only IAP antagonist found to function as a tumor
suppressor protein.
* Since ARTS does not bind to IAPs through the same binding motif
as other IAP antagonists (smac/Diablo), ARTS could be used in
combination with other IAP antagonists for achieving a
complementary potentially more effective pro-apoptotic effect.

ENTREPRENEURS
Dr. Sarit Larisch - Founder, CSO
Mrs. Keren Slijper - CEO

PROJECT STATUS
The company was established in 2004, and has recently been
approved for a third year in the Incubator program as well as
raising funds from an angle investor.
SimeTRA's technology is protected by three patent applications in
different stages of examination. The first patent protects
SimeTRA's rights to use ARTS and its derivatives as drug
candidates in cells that do not express ARTS or contain it in low
amounts, and specifically to use ARTS and its derivatives as drug
candidates in Leukemia. The second patent protects SimeTRA's
rights to use complexes containing ARTS and IAP as well as
ARTS-mimetic compounds for treating various diseases. The third
patent relates specifically to the use of a smaller derivative of
ARTS as a drug candidate.

COOPERATION REQUIRED
The company is seeking a partnership with a strategic investor,
who will provide the funds and expertise to continue the drug
development process.
-------------------------------------------------------
TEL. 972-4-6818801 E-MAIL: orit@new-pole.com WEB:
www.simetrapharm.com

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about